Catalyst Pharmaceuticals to Present Firdapse Phase 3 Trial Results at the 61st Annual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine

CORAL GABLES, Fla., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that safety and efficacy results from its Firdapse™ Phase 3 trial will be presented as part of an Industry Forum at the 61st Annual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) being held at the Savannah, Georgia International Trade and Convention Center, Oct. 29-Nov. 1. The Catalyst-sponsored forum will occur on Friday, Oct, 31 at 12:00 pm EDT and include presentations on the diagnosis and treatment of LEMS and Congenital Myasthenic Syndrome (CMS) by several Firdapse Phase 3 clinical study investigators and the Firdapse Expanded Access Program (EAP) by Catalyst's chief medical officer. Catalyst will also be exhibiting at booth #515 during the AANEM. The presentation materials will be posted at www.catalystpharma.com in the Investors section under Events & Presentations.

October 31st Agenda: "New Advances in the Diagnosis and Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)"

  • Clinical Features and Pathophysiology of Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndrome (CMS)
    Perry Shieh, MD, PhD
    Associate Professor
    Director, Neuromuscular Program
    UCLA Medical Center
  • Electrodiagnosis and Management of LEMS
    Yuen So, MD, PhD
    Professor of Neurology
    Chief, Neurology Clinic
    Stanford University Medical Center
  • Initial Firdapse Pivotal Phase 3 Study Safety Results
    Mazen Dimachkie, MD
    Professor of Neurology
    University of Kansas Medical Center
  • Initial FirdapsePivotal Phase 3 Study Efficacy Results
    Shin J. Oh, MD
    Distinguished Professor Emeritus
    University of Alabama at Birmingham Medical Center
  • Serving the LEMS Patient - Firdapse Expanded Access Program
    Charles Gorodetzky, MD, PhD
    Chief Medical Officer
    Catalyst Pharmaceuticals

Further information can be found at: http://catalystpharma.com/pdf/CPP14006_Invite_RD27R2_WEB.pdf

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, recently completed testing in a global, multi-center, pivotal Phase 3 trial and announced positive top-line data. Firdapse™ for the treatment of LEMS, has received Breakthrough Therapy and Orphan Drug Designations from the U.S. Food and Drug Administration (FDA). Firdapse™ is the first and only European approved drug for symptomatic treatment in adults with LEMS.

Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115) to treat infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder and Tourette Syndrome. CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted E.U. orphan medicinal product designation for the treatment of West Syndrome by the European Commission.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including whether the receipt of breakthrough therapy designation for Firdapse™ will expedite the development and review of Firdapse™ by the FDA or the likelihood that the product will be found to be safe and effective, whether an NDA for Firdapse™ will ever be accepted for filing by the FDA, the timing of any such NDA filing or acceptance, whether Catalyst will be the first company to receive an approval for amifampridine 3,4-DAP, giving it 7-year marketing exclusivity for its product, whether any of Catalyst's product candidates will ever be approved for commercialization or successfully commercialized, and those other factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2013 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CONTACT: Investor Contacts Brian Korb The Trout Group LLC (646) 378-2923 bkorb@troutgroup.com Media Contacts David Schull Matt Middleman, M.D. Russo Partners (212) 845-4271 (212) 845-4272 david.schull@russopartnersllc.com matt.middleman@russopartnersllc.com Company Contact Patrick J. McEnany Catalyst Pharmaceutical Partners, Inc. Chief Executive Officer (305) 529-2522 pmcenany@catalystpharma.com

Source:Catalyst Pharmaceutical Partners, Inc.